Portal de Periódicos da CAPES

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

2018; Elsevier BV; Volume: 392; Issue: 10152 Linguagem: Inglês

10.1016/s0140-6736(18)31924-x

1474-547X

J. Michael Gaziano, Carlos Brotons, Rosa Coppolecchia, Claudio Cricelli, Harald Darius, Philip B. Gorelick, George Howard, Thomas A. Pearson, Peter M. Rothwell, Luís M. Ruilope, Michał Tendera, Gianni Tognoni,

Inflammatory mediators and NSAID effects

The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event.